$59.79
-0.43 (-0.71%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PCVX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 3 with posted results
Held by 13 tracked-famous managers (D. E. Shaw & Co., Inc., MAVERICK CAPITAL LTD, Qube Research & Technologies Ltd, TWO SIGMA INVESTMENTS, LP, Artisan Partners Limited Partnership, +8 more) · FINRA short interest 14.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 16 sells · government filings 180d: 1 congress / 0 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy InfantsNCT06720038Percentage of subjects with any solicited local injection site adverse events (AE) within 7 days after each vaccinationRandomized · Quadruple-masked · Prevention | Phase 2 | Active, not recruiting | Biological: 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31 | Pneumococcal Vaccines | 900 | Dec 2027 | ≤ 499 d | 2026-05-15 |
| A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young AdultsNCT07616934Frequency of solicited local reactions (redness, swelling, and pain at injection site)Randomized · Quadruple-masked · Prevention | Phase 1 | Recruiting | Biological: Placebo, VAX-A1 Low, VAX-A1 Mid, VAX-A1 High | Group A Streptococcal Infection | 80 | Dec 2027 | ≤ 499 d | 2026-06-16 |
| A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of AgeNCT07365826For each of the 32 serotypes (the 31 serotypes included in VAX-31, and serotype 20B), the ratio (co-administration group to sequential administration group) of opsonophagocytic activity (OPA) geometric mean titers (GMT) in evaluable participantsRandomized · Quadruple-masked · Prevention | Phase 3 | Active, not recruiting | Biological: 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo | Pneumococcal Vaccines | 1,390 | Mar 2027 | ≤ 224 d | 2026-06-30 |
| Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal VaccinationNCT07425392Serotype-specific OPA geometric mean titers (GMT)Randomized · Quadruple-masked · Prevention | Phase 3 | Active, not recruiting | Biological: 31-valent pneumococcal conjugate vaccine, PCV20 | Pneumococcal Vaccines | 752 | Mar 2027 | ≤ 224 d | 2026-06-30 |
| Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49NCT07284654Serotype-specific OPA geometric mean titers (GMT) in 50 year olds and aboveRandomized · Quadruple-masked · Prevention | Phase 3 | Active, not recruiting | Biological: 31 valent pneumococcal conjugate vaccine, PCV20, PCV21 | Pneumococcal Vaccines | 4,049 | Jan 2027 | ≤ 165 d | 2026-05-15 |
| Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy InfantsNCT05844423Percentage of participants with any solicited local injection site Adverse Events (AE) within 7 days after each vaccinationRandomized · Quadruple-masked · Prevention | Phase 2 | Completed | Biological: 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24 | Pneumococcal Vaccines | 802 | 2025-08-25actual | — | 2025-09-11 |
| Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in AdultsNCT06151288results2025-07-28Percentage of Subjects Reporting Solicited Local Reactions Within 7 Days After Vaccination (Redness, Swelling, and Pain at Injection Site) in Each Age GroupRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: 31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine | Pneumococcal Vaccines | 1,015 | 2024-07-17actual | — | 2025-07-28 |
| Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older AdultsNCT05297578results2024-04-16Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After VaccinationRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: 24-Valent Pneumococcal Conjugate Vaccine, Pneumococcal 20-valent Conjugate Vaccine | Pneumococcal Vaccines | 207 | 2023-02-15actual | — | 2024-10-09 |
| Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in AdultsNCT05266456results2024-04-18Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age GroupRandomized · Quadruple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: 24 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine | Pneumococcal Vaccines | 835 | 2023-01-10actual | — | 2024-04-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19